[Skip to Content]

Claim CME

Coronavirus (COVID-19)

Coronavirus Disease 2019 (COVID-19) and Immune-Engaging Cancer Treatment

Educational Objective
To understand the COVID-19 infection risk for patients undergoing immune-engaging cancer treatment

1 Credit CME

JAMA Oncology

Published Online: May 20, 2020

Viewpoint

Article Information and Disclosures

Muhammad Bilal Abid, MD, MRCP^1,2;

Mustafa Mughal, MBBS³;

Muhammad Abbas Abid, MD⁴

Author Affiliations

¹Division of Hematology/Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee
²Division of Infectious Diseases, Department of Medicine, Medical College of Wisconsin, Milwaukee
³Department of Internal Medicine, Jinnah Postgraduate Medical Center, Karachi, Pakistan
⁴Department of Otolaryngology–Head and Neck Surgery, Johns Hopkins University School of Medicine, Baltimore, Maryland

Read article on JAMA Network

Read Article Claim CME

The coronavirus disease 2019 (COVID-19) pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is currently intensifying across the world. The US alone accounts for nearly one-third of the global disease burden and approximately one-fifth of deaths. The number of reported cases has been doubling weekly in the US, emphasizing the contagiousness of the disease among the US population due to a lack of immunity to the novel virus.¹

Claim CME

Sign in to take quiz and track your certificates

Buy This Activity

Article Information

Corresponding Author: Muhammad Bilal Abid, MD, MRCP, Division of Hematology/Oncology, Department of Medicine, Medical College of Wisconsin, 8701 Watertown Plank Rd, Milwaukee, WI 53226 (mabid@mcw.edu).

Published Online: May 20, 2020. doi:10.1001/jamaoncol.2020.2367

Conflict of Interest Disclosures: None reported.

References

WHO Coronavirus disease 2019 (COVID-19) situation report 86. March 16, 2020. Accessed April 15, 2020. https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200415-sitrep-86-covid-19.pdf?sfvrsn=c615ea20_6

Huang C , Wang Y , Li X , et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497-506. doi:10.1016/S0140-6736(20)30183-5 PubMed Google Scholar Crossref

Liang W , Guan W , Chen R , et al. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. Lancet Oncol. 2020;21(3):335-337. doi:10.1016/S1470-2045(20)30096-6 PubMed Google Scholar Crossref

Porcheddu R , Serra C , Kelvin D , Kelvin N , Rubino S . Similarity in case fatality rates (CFR) of COVID-19/SARS-COV-2 in Italy and China. J Infect Dev Ctries. 2020;14(2):125-128. doi:10.3855/jidc.12600 PubMed Google Scholar Crossref

Ruan Q , Yang K , Wang W , Jiang L , Song J . Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med. 2020;46(5):846-848. doi:10.1007/s00134-020-05991-x PubMed Google Scholar

Nishino M , Giobbie-Hurder A , Hatabu H , Ramaiya NH , Hodi FS . Incidence of programmed cell death 1 inhibitor-related pneumonitis in patients with advanced cancer: a systematic review and meta-analysis. JAMA Oncol. 2016;2(12):1607-1616. doi:10.1001/jamaoncol.2016.2453 PubMed Google Scholar Crossref

Lee DW , Gardner R , Porter DL , et al. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014;124(2):188-195. doi:10.1182/blood-2014-05-552729 PubMed Google Scholar Crossref

Favipiravir combined with tocilizumab in the treatment of corona virus disease. 2019. ClinicalTrials.gov identifier: NCT04310228. Updated April 10, 2020. Accessed May 11, 2020. https://clinicaltrials.gov/ct2/show/NCT04310228

A multicenter, randomized controlled trial for the efficacy and safety of tocilizumab in the treatment of new coronavirus pneumonia (COVID-19). Chinese Clinical Trial Registry identifier: ChiCTR2000029765. Accessed May 11, 2020. http://www.chictr.org.cn/showprojen.aspx?proj=49409

Russell CD , Millar JE , Baillie JK . Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury. Lancet. 2020;395(10223):473-475. doi:10.1016/S0140-6736(20)30317-2 PubMed Google Scholar Crossref

AMA CME Accreditation Information

Credit Designation Statement: The American Medical Association designates this Journal-based CME activity activity for a maximum of 1.00  AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to:

1.00 Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program;;
1.00 Self-Assessment points in the American Board of Otolaryngology – Head and Neck Surgery’s (ABOHNS) Continuing Certification program;
1.00 MOC points in the American Board of Pediatrics’ (ABP) Maintenance of Certification (MOC) program;
1.00 Lifelong Learning points in the American Board of Pathology’s (ABPath) Continuing Certification program; and
1.00 CME points in the American Board of Surgery’s (ABS) Continuing Certification program

It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting MOC credit.